NCT04690751View on ClinicalTrials.gov

Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions
Healthy
Interventions
DRUG

Cenobamate 200Mg Tab Fasted

Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.

DRUG

Cenobamate Oral Suspension Fed

Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.

DRUG

Cenobomate Oral Suspension Fasted

Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.

Trial Locations (1)

84124

PRA Health Sciences Salt Lake City, Millcreek

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT04690751 - Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet | Biotech Hunter | Biotech Hunter